Chief Executive Officer
Peter Fernandes has served as our Principal Executive Officer since November 2021 and has served as our Chief Regulatory, Safety & Quality Officer since May 2015. Prior to joining us, Mr. Fernandes was Vice President of Global Regulatory Affairs at Ikaria Inc., from October 2012 to May 2015, and in this capacity also led our regulatory group since its inception in February 2014. Previously, he led Regulatory Affairs and Quality Assurance for OptiNose, Inc. from October 2010 to September 2012, was Vice President US Drug Regulatory Affairs Respiratory and US DRA Respiratory Franchise Head for Novartis Pharmaceuticals from November 2007 to October 2010. He has also served as the Head of US Development Site and Vice President of Regulatory Affairs and Quality Assurance at Altana Pharma, a subsidiary of Nycomed Inc., and led the US Respiratory and GI Drug Regulatory Affairs group at Boehringer Ingelheim. Mr. Fernandes has over 30 years of experience leading cross functional global development teams covering respiratory and cardiovascular diseases with successful US and global submissions and approvals obtained for a number of well-known drugs e.g., Flomax, Spiriva, Omnaris. Mr. Fernandes also serves as Co-Chair of the Pulmonary Vascular Research Institute (PVRI) Innovative Drug Development Initiative that is instrumental in developing novel regulatory endpoints and clinical trial design for Pulmonary Hypertension (PH) in collaboration with academia, industry and regulators. Mr. Fernandes has an M. Pharm. from the Grant Medical College and a B. Pharm. from the K.M. K College of Pharmacy, both at the University of Bombay in India.
Parag Shah, Ph.D.
Vice President, Business Operations
Parag Shah, Ph.D. has served as our Vice President of Business Operations since April 2016 with responsibilities for Project Management, Supply Distribution, Pre-Clinical and Business Development activities. Prior to joining Bellerophon, Dr. Shah was Principal Scientist at Pfizer from 2004 through 2010 where he was responsible for leading multiple parenteral and liquid formulation development teams. In addition, Dr. Shah was a member of multiple Limited Duration Teams including serving as Pfizer’s Team Lead for the Nanoparticle Network responsible for internal and external evaluation of nanoparticle technologies. Dr. Shah joined Ikaria as Parenteral Development Lead in 2010 and assumed additional responsibilities in 2012 as Director, Pharmaceutical Science, covering both Pharmaceutical Development and Clinical Supply Management.
Dr. Shah received his Bachelor’s degree from Carnegie Mellon and his Ph.D. in Chemical Engineering from The University of Texas at Austin.
Mr. Hanuschek has joined the management team as a financial advisor. Mr. Hanuschek has extensive experience with public company finance that includes SEC and multinational reporting and compliance, strategic planning, risk management, internal control and process improvement, human resource and benefit management, mergers / acquisitions, and equity / debt financing. Most recently Mr. Hanuschek has leveraged this experience, specializing in interim CFO support and financial consulting since 2016 with MSH Financial Advisory. Prior to that, Mr. Hanuschek held executive management roles with several technology oriented publicly traded companies that included Chief Executive Officer of CTI Group (Holdings) Inc. from 2014 to 2016 and as Chief Financial Officer from 2000 to 2014, Chief Financial Officer and Senior Vice President for IGI, Inc from 1999 to 2000, and Chief Financial Officer for ICC Technologies, Inc. from 1994 to 1998. Mr. Hanuschek began his career at PriceWaterhouseCoopers where he served as Senior Manager. Mr. Hanuschek is a certified public accountant and holds a bachelor’s degree in accounting from the Pennsylvania State University.